Ajaya was founded by Mohit S. in 2024.

Who are Ajaya's investors?

Ajaya's investors include The Innovation Space, Ben Franklin Technology Partners.

How much funding has Ajaya raised?

Ajaya has disclosed $150K raised across 1 of its 2 known rounds.

Where is Ajaya headquartered?

Ajaya is headquartered in Philadelphia, US.

Ajaya

Philadelphia, US · Founded 2024 · Delaware corporation · 4 employees on LinkedIn · 6 known investors

Find your way into Ajaya

Ajaya Bio develops bispecific therapies designed to eliminate disease-driving cells while sparing healthy ones, using its BOLT-360 discovery platform built around hybrid binders, precise activation, and advanced linkers. The company operates in the biotherapeutics field.

Biotech Deep Tech

Founders & leadership

Ajaya was founded in 2024 by Mohit S..

Mohit S.inFounderMohit S. has 15+ years of experience in immunology, oncology, and genetic medicine, including leadership roles at Orion, Cellectis, Interius, and Spark Therapeutics, with publications and patent filings in the field. He founded Ajaya Bio to develop bispecific therapies for autoimmune diseases and cancer.

Mohit SachdevainNamed on SEC filing

Investors · 6

The Innovation SpaceWilmington · $200K

Ben Franklin Technology PartnersreportedHarrisburg · $50K – $250K

Also in the syndicate · 4

BioAdvance CapitalFreeflow VenturesleadRK Family TrustleadTangent Advisorslead

Reported raises · per SEC filings

Form D private placements

$150K disclosed across 1 of 2 rounds · 2024–2026

▶$150KraisedJul 2024 · 2 investors · Other Technology

Rule 506(b)

Officers, directors & promoters on the filing

Mohit SachdevaExecutive Officer, Director

Offering amount: $300K
Amount sold: $150K
First sale: Apr 2024
Incorporated: Corporation, Delaware, 2024
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Ideaya Biosciences4 shared keywordsIDEAYA is a precision medicine oncology company developing first-in-class targeted therapies and rational drug combinations for molecularly defined, hard-to-treat cancers. Its lead candidate, darovasertib, is in late-stage trials for uveal melanoma, with a pipeline spanning PKC inhibition, ADC+DDR combinations, the MTAP pathway, and KAT6/7 inhibition.

Companies competing with Ajaya for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Commercial papers explained: How companies raise short-term funds | Company News - Business Standardbusiness-standard.com · Jul 2026

Ajaya Bio plans Series A to advance autoimmune treatment and grow in Philadelphiatechnical.ly · Mar 2026

Payments firm Juspay raises $60 mn days after open-sourcing routing layer | Company News - Business Standardbusiness-standard.com · Apr 2025

CURRYiT has raised INR 4.5 Cr in Seed funding round co-led by RK Family Trust, Tangent Advisors, and Freeflow Ventures. - Enablersenablersinvestment.com · Aug 2024

CURRYiT raises Rs 4.5cr in seed round to scale-up manufacturing & distributionbusiness-standard.com · Aug 2024

Frequently asked questions

What does Ajaya do?: Ajaya Bio develops bispecific therapies designed to eliminate disease-driving cells while sparing healthy ones, using its BOLT-360 discovery platform built around hybrid binders, precise activation, and advanced linkers. The company operates in the biotherapeutics field.
Who founded Ajaya?: Ajaya was founded by Mohit S. in 2024.
Who are Ajaya's investors?: Ajaya's investors include The Innovation Space, Ben Franklin Technology Partners.
How much funding has Ajaya raised?: Ajaya has disclosed $150K raised across 1 of its 2 known rounds.
Where is Ajaya headquartered?: Ajaya is headquartered in Philadelphia, US.